Paraneoplastic subacute sensory neuropathy with triple positive antineuronal antibodies associated with small-cell lung cancer.
immunology
malignant disease and immunosuppression
neurology
respiratory cancer
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
24 Aug 2020
24 Aug 2020
Historique:
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
16
2
2021
Statut:
epublish
Résumé
A 67-year-old woman with a history of smoking and cardiovascular risk factors was admitted to the emergency room for uncontrolled diabetes, loss of appetite, nausea, significant weight loss and asthenia. The initial investigation, including cerebral and gastrointestinal explorations, were normal. One month later, she started presenting severe asymmetric proprioceptive ataxia of the lower extremities. She also reported paresthesia and neuropathic pain in both feet and ankles. A positron emission tomography (PET)-scanner showed a hypermetabolic nodule in the right lung. The neurological symptoms were attributed to paraneoplastic sensory and dysautonomic neuropathy, even though the bronchoscopic biopsies came back negative at first. Anti-Hu, anti-CV2/CRMP5 and anti-SOX1 antibodies were documented. Due to the severity and rapid progression of symptoms (from the lower to the upper limbs), corticosteroids, intravenous immunoglobulins and immunosuppressants were introduced prior to biopsies revealing a small-cell lung cancer. Despite these treatments and antineoplastic chemotherapy, her status deteriorated rapidly.
Identifiants
pubmed: 32843376
pii: 13/8/e235668
doi: 10.1136/bcr-2020-235668
pmc: PMC7449276
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antineoplastic Agents
0
Autoantibodies
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
World J Clin Oncol. 2014 Aug 10;5(3):197-223
pubmed: 25114839
Neurol India. 2017 Sep-Oct;65(5):1127-1128
pubmed: 28879908
Lancet Neurol. 2012 Jun;11(6):521-34
pubmed: 22608666
Curr Neurol Neurosci Rep. 2017 Aug 23;17(10):79
pubmed: 28836102
J Neurol Sci. 2016 Oct 15;369:342-346
pubmed: 27653921
Cancer. 2015 Mar 1;121(5):664-72
pubmed: 25336398
J Neuroimmunol. 2010 Sep 14;226(1-2):177-80
pubmed: 20701982
Front Psychiatry. 2019 Apr 04;10:207
pubmed: 31019473
J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792
pubmed: 29084869
Mol Cancer. 2011 Mar 30;10:33
pubmed: 21450098
Muscle Nerve. 2018 Jan;57(1):33-39
pubmed: 28556429
Ann Indian Acad Neurol. 2008 Apr;11(2):89-97
pubmed: 19893645
J Neurooncol. 2003 Jun;63(2):187-90
pubmed: 12825823
Clin Liver Dis. 2019 Feb;23(1):141-155
pubmed: 30454828
Front Immunol. 2019 Apr 12;10:769
pubmed: 31031763
Brain. 2001 Jun;124(Pt 6):1138-48
pubmed: 11353730
Neurology. 1999 Nov 10;53(8):1719-23
pubmed: 10563618
Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):200-214
pubmed: 31193945
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593